NYSE · AMGN
Healthcare · Drug Manufacturers - General
$414.61
Up+$1.05 (+0.25%)
Updated Sep 28, 2026, 4:09 PM
SID Score
6.9/10
Composite research score
Smart Money
47/100
Neutral
Price performance · AMGN
1M range · 19 trading sessions · Daily adjusted prices
Prices through Sep 25, 2026
AMGN closed at $414.61 after 19 trading sessions, down 3.55% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 25, 2026 | $408.25 | $415.20 | $404.19 | $414.61 | 2.21M |
| Sep 24, 2026 | $406.09 | $409.99 | $403.88 | $406.04 | 2.53M |
| Sep 23, 2026 | $410.09 | $415.76 | $404.34 | $406.09 | 2.82M |
| Sep 22, 2026 | $405.25 | $412.995 | $398.52 | $410.24 | 3.72M |
| Sep 21, 2026 | $385.71 | $394.50 | $381.90 | $393.16 | 2.89M |
| Sep 18, 2026 | $378.51 | $386.50 | $378.51 | $385.65 | 8.53M |
| Sep 17, 2026 | $379.15 | $382.49 | $376.08 | $379.78 | 3.23M |
| Sep 16, 2026 | $377.01 | $379.11 | $374.46 | $376.35 | 2.4M |
| Sep 15, 2026 | $380.23 | $381.04 | $375.15 | $375.65 | 2.61M |
| Sep 14, 2026 | $381.94 | $384.61 | $376.76 | $381.50 | 2.71M |
| Sep 11, 2026 | $386.135 | $386.99 | $377.22 | $377.35 | 2.27M |
| Sep 10, 2026 | $387.84 | $391.666 | $381.51 | $382.47 | 3.43M |
| Sep 9, 2026 | $393.065 | $395.55 | $389.28 | $391.27 | 2.92M |
| Sep 8, 2026 | $408.90 | $410.025 | $391.17 | $393.17 | 6.83M |
| Sep 4, 2026 | $437.03 | $441.85 | $435.00 | $437.23 | 1.66M |
| Sep 3, 2026 | $445.67 | $445.815 | $438.0801 | $444.12 | 1.84M |
| Sep 2, 2026 | $440.65 | $445.57 | $435.00 | $442.84 | 2.29M |
| Sep 1, 2026 | $435.301 | $438.65 | $431.00 | $438.12 | 2.36M |
| Aug 31, 2026 | $428.59 | $431.85 | $426.00 | $429.88 | 2.34M |
The latest Smart Investors Daily articles mentioning AMGN.
AMGN research
Company profile and research snapshot.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | HSBC | Hold | — |
| Sep 8, 2026 | BMO Capital | Market Perform | — |
| Sep 8, 2026 | Cantor Fitzgerald | Neutral | — |
| Sep 4, 2026 | Wells Fargo | Equal-Weight | — |
| Aug 20, 2026 | Piper Sandler | Overweight | — |
Generated Sep 28, 2026, 3:04 PM
Amgen shares are up 0.26% today, outpacing the broader market amid a mixed news cycle featuring pipeline developments and strategic capital allocation moves. The biotech giant is balancing positive drug development momentum with a notable real estate transaction that could strengthen its balance sheet.
Bottom line: Amgen's modest gains reflect a balanced narrative of encouraging pipeline developments offset by incremental capital redeployment through asset sales. Investors should focus on upcoming pipeline milestones and clinical data as key catalysts, while monitoring the competitive landscape and regulatory environment in healthcare.
Yahoo · Sep 27, 2026
Amgen Inc. (NASDAQ:AMGN)’s experimental drug dazodalibep met the main goal of a late-stage trial for Sjögren’s disease. After 48 weeks, patients with moderate-to-severe disease activity showed statistically significant and clinically meaningful improvements. Most adverse events were mild to moderate, and only a small number of patients stopped treatment. Sjögren’s affects about 1% of the global […]
Yahoo · Sep 27, 2026
Amgen Inc. (NASDAQ:AMGN) has sold its office campus in Deerfield, Illinois, for $151 million. The buyer is an entity tied to Mesirow, a financial services firm based in Chicago. Amgen is not leaving. It has signed a long-term lease to stay on the roughly 660,000-square-foot campus, where it occupies one of the three buildings. The […]
Yahoo · Sep 26, 2026
And there could be more positive developments ahead.
Yahoo · Sep 25, 2026
Mesirow CEO Richard S. Price with 1 Horizon Way in Deerfield (Getty, Mesirow, Google Maps)An entity tied to Chicago financial services firm Mesirow bought the Amgen office complex in Deerfield in a sale-leaseback deal for $151 million. The deal for the property, which spans 660,000 square feet of office space in three buildings at 1 Horizon Way along I-294 in suburban Deerfield, is rare for a site of its 70-acre size, according to Crain’s. The suburbs still suffer from high vacancy rates and sha
Interpretive context generated from the platform’s current data sources.
Amgen Inc. shares closed at $414.61, reflecting a daily decline of approximately 2.50% per SID market data. Despite the near-term pullback, the stock has delivered a strong 27.18% gain over the trailing twelve months and a 15.71% advance over the past three months. However, one-month performance shows a 5.84% decline, indicating recent selling pressure. From a technical standpoint, AMGN trades above both its 50-day moving average of $404.70 and its 200-day moving average of $368.57, suggesting the longer-term uptrend remains intact according to Massive/Polygon data. The 14-day relative strength index stands at 40.4, positioning the stock closer to oversold territory without yet triggering a classic oversold signal. Average daily trading volume is approximately 2.89 million shares. Amgen's beta of 0.472 indicates significantly lower volatility relative to the broader market, consistent with its defensive healthcare sector positioning.
Amgen Inc. carries a market capitalization of approximately $209.2 billion, positioning it among the largest biotechnology companies globally. Per SID market data, the stock trades at a price-to-earnings ratio of 27.13, which sits above the historical average for large-cap healthcare names. The PEG ratio of 2.72 suggests the current valuation may be elevated relative to the company's earnings growth trajectory, as values above 1.0 generally indicate a premium to growth. Amgen's price-to-book ratio stands at 24.16, reflecting the capital-light, intellectual-property-driven nature of biopharmaceutical businesses according to SEC filings. The company offers a dividend yield of approximately 2.49%, providing meaningful income relative to sector peers. This yield, combined with the company's consistent history of capital returns, positions AMGN as a hybrid growth-and-income holding within institutional healthcare portfolios, though the elevated PEG ratio warrants attention from value-oriented investors.
Amgen Inc. registers a composite smart money score of 44, reflecting a neutral overall signal per SID market data. The institutional component scores a perfect 25 out of 25, indicating robust and sustained accumulation by large fund managers as reported in 13F institutional filings. In contrast, the insider sentiment score sits at 8.6 out of 25, and dark pool activity scores just 5.0 out of 25, suggesting limited conviction from corporate insiders and off-exchange participants. Congressional trading interest is similarly muted at 5.2 out of 25. According to SEC Form 4 filings, there have been 15 insider transactions over the past 90 days, comprising 9 purchases and 6 sales. The net insider buying tilt is a modestly constructive data point, though the relatively low insider score indicates these transactions may be small in dollar magnitude. The divergence between strong institutional positioning and subdued insider activity creates a mixed smart money profile for AMGN, warranting continued monitoring of both channels.
Amgen Inc. has delivered three consecutive quarterly earnings beats according to company earnings reports. In the most recent reported quarter, the company posted earnings per share of $6.29 against an analyst estimate of $5.60, representing a positive surprise of $0.69 or approximately 12.3%. The prior quarter saw EPS of $5.15 versus a $4.76 estimate, a $0.39 upside surprise, while the quarter before that produced $5.29 against a $4.75 consensus, beating by $0.54. This consistent pattern of outperformance suggests Amgen's operational execution has exceeded Wall Street expectations. Looking ahead, analyst estimates project EPS of approximately $4.81 for the upcoming reporting period per consensus data. The trajectory of estimate beats has averaged roughly $0.54 per quarter across the last three periods, providing a meaningful baseline for evaluating whether Amgen can sustain its pattern of exceeding consensus forecasts.
Recent Wall Street analyst activity for Amgen Inc. reflects a shifting sentiment toward a more cautious stance per SID consensus data. In September 2026, HSBC downgraded AMGN from Buy to Hold, while BMO Capital downgraded the stock from Outperform to Market Perform. Cantor Fitzgerald reiterated its Neutral rating, and Wells Fargo maintained an Equal-Weight position, reinforcing the growing consensus toward a hold-equivalent view. Among the five most recent analyst actions tracked, only Piper Sandler maintained a bullish Overweight rating according to Wall Street analyst reports. The two downgrades occurring within a two-day span on September 8 and September 10 suggest a coordinated reassessment of AMGN's risk-reward profile, potentially reflecting the stock's 27.18% trailing twelve-month appreciation and elevated PEG ratio of 2.72. The current analyst landscape indicates a predominantly neutral consensus, with limited near-term catalysts identified to drive upgrades from the broader coverage universe.
The latest Smart Investors Daily articles mentioning AMGN.
